AR052775A1 - Comprimidos bicapa de telmisartan y simvastatina - Google Patents

Comprimidos bicapa de telmisartan y simvastatina

Info

Publication number
AR052775A1
AR052775A1 ARP050104270A ARP050104270A AR052775A1 AR 052775 A1 AR052775 A1 AR 052775A1 AR P050104270 A ARP050104270 A AR P050104270A AR P050104270 A ARP050104270 A AR P050104270A AR 052775 A1 AR052775 A1 AR 052775A1
Authority
AR
Argentina
Prior art keywords
telmisartan
simvastatina
bicapa
comprimidos
tablet
Prior art date
Application number
ARP050104270A
Other languages
English (en)
Inventor
Anja Kohlrausch
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36145644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052775(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR052775A1 publication Critical patent/AR052775A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Un comprimido bicapa comprende una primera capa formulada para la liberacion inmediata del antagonista del receptor de angiotensina II telmisartán desde una matriz de disolucion de comprimido y una segunda capa formulada para la liberacion inmediata del inhibidor de la HMG-CoA reductasa simvastatina desde una matriz de disgregacion o erosion de comprimido.
ARP050104270A 2004-10-12 2005-10-12 Comprimidos bicapa de telmisartan y simvastatina AR052775A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04024239 2004-10-12

Publications (1)

Publication Number Publication Date
AR052775A1 true AR052775A1 (es) 2007-04-04

Family

ID=36145644

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104270A AR052775A1 (es) 2004-10-12 2005-10-12 Comprimidos bicapa de telmisartan y simvastatina

Country Status (17)

Country Link
US (1) US20060078615A1 (es)
EP (1) EP1802283A2 (es)
JP (1) JP2008515838A (es)
KR (1) KR20070064366A (es)
CN (1) CN101052380A (es)
AR (1) AR052775A1 (es)
AU (1) AU2005293773A1 (es)
BR (1) BRPI0516073A (es)
CA (1) CA2578447A1 (es)
EA (1) EA200700765A1 (es)
EC (1) ECSP077381A (es)
IL (1) IL182455A0 (es)
NO (1) NO20071375L (es)
TW (1) TW200628174A (es)
UY (1) UY29160A1 (es)
WO (1) WO2006040085A2 (es)
ZA (1) ZA200701098B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
RU2453307C2 (ru) * 2006-10-30 2012-06-20 Ханол Биофарма Ко.Лтд Комплексная фармацевтическая композиция с контролируемым высвобождением, содержащая блокаторы рецепторов ангиотензина-ii и ингибиторы гидроксиметилглутарил-кофермент а-редуктазы
WO2008068217A2 (en) * 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
CN101219120B (zh) * 2007-12-27 2011-02-23 江苏万邦生化医药股份有限公司 替米沙坦分散片及其制备方法
WO2009120052A1 (es) * 2008-03-24 2009-10-01 Laboratorios Pisa, S.A. De C.V. Composición farmacéutica con efecto sinérgico para el tratamiento de hipertensión arterial y dislipidemia
US20110117194A1 (en) 2008-04-29 2011-05-19 Hanall Biopharma Co., Ltd. Pharmaceutical formulation containing angiotensin-ii receptor blocker
WO2010021473A2 (ko) * 2008-08-19 2010-02-25 한올제약주식회사 약제학적 제제
CZ2008740A3 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
AR086675A1 (es) * 2011-06-14 2014-01-15 Merck Sharp & Dohme Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
WO2013021441A1 (ja) * 2011-08-05 2013-02-14 富士通株式会社 データ処理システム、およびデータ処理方法
KR101466617B1 (ko) * 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
AU2015292212B2 (en) 2014-07-25 2019-03-14 Laurent Pharmaceuticals Solid oral formulation of fenretinide
US10406127B2 (en) 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide
CN104739833A (zh) * 2015-02-16 2015-07-01 江苏欧信医药化工有限公司 含替米沙坦和瑞舒伐他汀钙的复方双层片剂及其制备方法
WO2016200694A1 (en) * 2015-06-10 2016-12-15 Hackensack University Medical Center Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases
KR101883091B1 (ko) * 2017-01-18 2018-07-27 아주대학교산학협력단 안지오텐신 수용체 차단제 및 HMG-CoA 환원효소 억제제를 유효성분으로 함유하는 이층정 복합제제 및 이의 제조방법
CN112168801A (zh) * 2020-10-22 2021-01-05 哈药集团技术中心 一种辛伐他汀片的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
ES2298351T5 (es) * 2002-01-16 2012-01-26 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Método para producir un comprimido farmacéutico de dos capas que comprenden telmisartán e hidroclorotiazida.
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
DK1587584T3 (da) * 2003-01-16 2007-09-24 Boehringer Ingelheim Int Farmaceutisk kombination til profylakse eller behandling af kardiovaskulære, kardiopulmonale, pulmonale eller renale sygdomme
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets

Also Published As

Publication number Publication date
UY29160A1 (es) 2006-05-31
WO2006040085A3 (en) 2007-03-15
TW200628174A (en) 2006-08-16
ZA200701098B (en) 2009-06-24
CA2578447A1 (en) 2006-04-20
IL182455A0 (en) 2007-07-24
AU2005293773A1 (en) 2006-04-20
EP1802283A2 (en) 2007-07-04
JP2008515838A (ja) 2008-05-15
NO20071375L (no) 2007-05-10
BRPI0516073A (pt) 2008-08-19
WO2006040085A2 (en) 2006-04-20
ECSP077381A (es) 2007-05-30
US20060078615A1 (en) 2006-04-13
CN101052380A (zh) 2007-10-10
KR20070064366A (ko) 2007-06-20
EA200700765A1 (ru) 2007-10-26

Similar Documents

Publication Publication Date Title
AR052775A1 (es) Comprimidos bicapa de telmisartan y simvastatina
ECSP066779A (es) Comprimido multicapas
UY29188A1 (es) Comprimido comprendiendo capa de telmisartan en matriz de disolucion y capa de amlodipino en matriz de desintegracion y metodo de preparacion
CY1114929T1 (el) Φαρμακευτικο δισκιο δυο-στιβαδων το οποιο περιλαμβανει τελμισαρτανη και ενα διουρητικο
AR052104A1 (es) Formas de dosificacion de inhibidores de la proteina de transferencia de esteres de colesterilo e inhibidores de la hmg- coa reductasa
CY1111350T1 (el) Φαρμακευτικη συνθεση
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
WO2009058950A3 (en) Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
CO6311069A2 (es) Cápsulas que comprenden ácido acetilsalicílico, un inhibidor de la hmg-coa reductasa y un ace inhibidor para la prevención de enfermedades cardiovasculares
ECSP088987A (es) Formas de dosificación sólidas de valsartan, amlodipina, e hidroclorotiazida, y método para elaborarlas
NO20073396L (no) Farmasoytiske kombinasjoner av en angiotensinreceptorantagonist og en NEP-inhibitor
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
EA201001312A1 (ru) Твердая фармацевтическая композиция, содержащая непептидный антагонист рецептора ангиотензина ii и диуретик
CL2008003799A1 (es) Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
MX2007011607A (es) Metodo para reducir el riesgo de eventos cardiovasculares adversos (cv) asociados con la administracion de agentes farmaceuticos que favorecen los eventos cv.
AR061487A1 (es) Una composicion farmaceutica en forma de comprimido multicapa de tetraciclina
ECSP045195A (es) Un comprimido farmacéutico de dos capas que comprende telmisartán y un diurético y la preparación de dicho comprimido
TH79790A (th) ยาเม็ดชนิดสองชั้น
ECSP085195A (es) Un comprimido farmaceutico de dos capas que comprenden telmisartan y un diurético y la preparación de dicho comprimido
TH79244B (th) ยาเม็ดแบบมีสองชั้น
TH79244A (th) ยาเม็ดแบบมีสองชั้น
ECSP045052A (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
AR047700A1 (es) Composicion farmaceutica para la liberacion mejorada de diclofenac
CL2008002388A1 (es) {5-(4-bromo-fenil)-6-[2-(5-bromo-pirimidin-2-iloxi)-etoxi]-pirimidin-4-il}-sulfamida, inhibidor de la endotelina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hipertension, hipertension arterial, enfermedades coronarias, entre otras.

Legal Events

Date Code Title Description
FB Suspension of granting procedure